Trial Profile
Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Demonstrate That a Single Infusion of Tezosentan Has Minimal Effect on Blood Pressure in Patients With Pulmonary Arterial Hypertension, Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or a Combination of Both.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Tezosentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 15 Aug 2014 New trial record
- 27 Jun 2012
- 27 May 2011